Mark Bieniarz, MD
Interventional Cardiology · Albuquerque, NMNPI 1174776868
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Abiomed at 42.6% of the total. Reporting peaked in 2024 at $60,971 and has fallen 56.1% since, to $26,792 in 2025. Among interventional cardiology clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 940 payments — averaging $220.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$88K
- Edwards Lifesciences$72K
- Amgen$21K
- Terumo Medical Corporation$7K
- Merit Medical Systems Inc$4K
- Abbott$3K
- plus $11K from 29 others
Across 11 payments — averaging $8313.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$91K
- Abiomed$407
What the payments were for
- Consulting fees$60,14329%
- Speaking & faculty fees$87,50242%
- Travel & lodging$33,42516%
- Food & beverage$26,38513%
- Education$160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 162 | $88,441 |
| Edwards Lifesciences | 186 | $72,339 |
| Amgen | 67 | $21,289 |
| Terumo Medical Corporation | 6 | $6,892 |
| Merit Medical Systems Inc | 2 | $4,400 |
| Abbott | 103 | $2,993 |
| Ancora Heart, Inc. | 17 | $2,647 |
| Boston Scientific | 100 | $2,080 |
| Novartis | 56 | $963 |
| Philips North America LLC | 37 | $956 |
| Medtronic(2 entities) | 31 | $889 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 30 | $575 |
| W. L. Gore & Associates, Inc. | 16 | $476 |
| Johnson & Johnson | 22 | $423 |
| E.r. Squibb & Sons, L.L.C. | 20 | $372 |
| AstraZeneca | 22 | $343 |
| Cardiovascular Systems Inc. | 15 | $266 |
| Livanova USA, Inc. | 3 | $231 |
| Pfizer | 10 | $204 |
| Baxter Healthcare | 4 | $139 |
| Shockwave Medical, Inc | 7 | $108 |
| Biosense Webster, Inc. | 4 | $78 |
| Inspire Medical Systems, Inc. | 2 | $73 |
| Chiesi USA, Inc. | 4 | $57 |
| Merck | 2 | $39 |
| Boehringer Ingelheim | 2 | $29 |
| Tactile Systems Technology Inc | 2 | $29 |
| Novo Nordisk | 1 | $28 |
| Cordis US CORP. | 1 | $21 |
| Teleflex LLC | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Itamar Medical Inc | 1 | $14 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
| Bayer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$85,220
- Edwards SAPIEN 3 Transcatheter Heart Valve$44,133
- Repatha$20,383
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$14,043
- Glidesheath$5,958
- SAPIEN 3 Ultra RESILIA$2,899
- AccuCinch$2,452
- PASCAL$1,768
- TRICLIP$791
- Mitra Clip system$243
- CoreValve Evolut$232
- AVEIR$183
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$149
- EVOQUE$145
- GENERAL - THERAPIES$141
- TR Band$134
- LifeSPARC$132
- Xience Sierra Coronary Stent$120
- VYNDAQEL$116
- (6571) Eagle Eye$110
How this compares
$207,470 in reported general payments places this provider in the 95th percentile of 25 interventional cardiology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 334 | $394,133 |
| EntrestoSacubitril/Valsartan | 103 | $128,251 |
| Repatha SureclickEvolocumab | 106 | $72,227 |
| XareltoRivaroxaban | 56 | $68,294 |
| BrilintaTicagrelor | 39 | $37,161 |
| Repatha PushtronexEvolocumab | 54 | $35,268 |
| Repatha SyringeEvolocumab | 20 | $17,147 |
| Rosuvastatin Calcium | 763 | $13,145 |
| Nebivolol Hcl | 263 | $13,036 |
| JardianceEmpagliflozin | 12 | $10,914 |
| Irbesartan | 348 | $7,919 |
| Praluent PenAlirocumab | 16 | $7,471 |
| Varenicline Tartrate | 24 | $7,225 |
| VascepaIcosapent Ethyl | 11 | $7,153 |
| Atorvastatin Calcium | 470 | $6,062 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $204 | $394,133334 claims |
| NovartisEntresto | $963 | $128,251103 claims |
| Johnson & JohnsonXarelto | $423 | $68,29456 claims |
| AstraZenecaBrilinta | $343 | $37,16139 claims |
| Boehringer IngelheimJardiance | $29 | $10,91412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 25 interventional cardiology providers in New Mexico.
Other interventional cardiology in Albuquerque
- Raymond YauAlbuquerque$171K
- Robert FedericiAlbuquerque$77K
- Sharif HalimAlbuquerque$22K
- Geoffrey KunzAlbuquerque$22K
- Charles KimAlbuquerque$9K
- Harvey WhiteAlbuquerque$3K
- Guilherme MarinAlbuquerque$3K
- James BlankenshipAlbuquerque$2K
- John BattyAlbuquerque$82
- Abdul KhanLas Cruces$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.